Literature DB >> 12874201

The immune response modifier and Toll-like receptor 7 agonist S-27609 selectively induces IL-12 and TNF-alpha production in CD11c+CD11b+CD8- dendritic cells.

Christie L Doxsee1, Tony R Riter, Michael J Reiter, Shelia J Gibson, John P Vasilakos, Ross M Kedl.   

Abstract

IL-12 and TNF-alpha production by dendritic cells (DCs) is a critical step in the initiation of local inflammation and adaptive immune responses. We show in this study that a small molecule immune response modifier that is a Toll-like receptor 7 (TLR7) agonist induces IL-12 and TNF-alpha production from murine CD11c(+)CD11b(+)CD8(-) DCs, a subset not previously known for this activity. Stimulation of these DCs through TLR7 in vivo induces significant cytokine production even 12 h after initial stimulation, as well as migration of the DC into T cell zones of the lymphoid tissue. In contrast, stimulation through TLR4 and TLR9 induced IL-12 production predominantly from CD8(+) DCs, consistent with previously published data. All TLR stimuli induced the increase in surface expression of the activation markers B7-1, B7-2, and class II in both CD8(+) and CD8(-) DCs, demonstrating that CD8(+) DCs do respond to TLR7-mediated stimuli. To date this is the only known stimuli to induce preferential cytokine production from CD8(-) DCs. Given the efficacy of TLR7 agonists as antiviral agents, the data collectively indicate that stimulation of CD8(-) DCs through TLR7 most likely plays a role in the generation of antiviral immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12874201     DOI: 10.4049/jimmunol.171.3.1156

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

2.  TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway.

Authors:  Jason Z Oh; Jonathan S Kurche; Matthew A Burchill; Ross M Kedl
Journal:  Blood       Date:  2011-08-02       Impact factor: 22.113

3.  A novel synthetic adjuvant enhances dendritic cell function.

Authors:  Karen S M Phillipps; Michelle N Wykes; Xue Q Liu; Melissa Brown; Joanne Blanchfield; Istvan Toth
Journal:  Immunology       Date:  2008-12-26       Impact factor: 7.397

4.  Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

Authors:  Kathrin Kastenmüller; Ulrike Wille-Reece; Ross W B Lindsay; Lauren R Trager; Patricia A Darrah; Barbara J Flynn; Maria R Becker; Mark C Udey; Björn E Clausen; Botond Z Igyarto; Daniel H Kaplan; Wolfgang Kastenmüller; Ronald N Germain; Robert A Seder
Journal:  J Clin Invest       Date:  2011-04-11       Impact factor: 14.808

Review 5.  Engineering immunity: Modulating dendritic cell subsets and lymph node response to direct immune-polarization and vaccine efficacy.

Authors:  Jardin Leleux; Alexandra Atalis; Krishnendu Roy
Journal:  J Control Release       Date:  2015-10-20       Impact factor: 9.776

6.  Direct activation of antigen-presenting cells is required for CD8+ T-cell priming and tumor vaccination.

Authors:  Wolfgang Kratky; Caetano Reis e Sousa; Annette Oxenius; Roman Spörri
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

7.  Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma.

Authors:  Howard L Kaufman; Gail Deraffele; Josephine Mitcham; Dorota Moroziewicz; Seth M Cohen; Karl S Hurst-Wicker; Ken Cheung; David S Lee; Joseph Divito; Magalese Voulo; Julie Donovan; Kate Dolan; Kelledy Manson; Dennis Panicali; Ena Wang; Heidi Hörig; Francesco M Marincola
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

8.  In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants.

Authors:  Eric M Bachelder; Tristan T Beaudette; Kyle E Broaders; Jean M J Fréchet; Mark T Albrecht; Alfred J Mateczun; Kristy M Ainslie; John T Pesce; Andrea M Keane-Myers
Journal:  Mol Pharm       Date:  2010-06-07       Impact factor: 4.939

9.  Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Authors:  Mohamed L Salem; C Marcela Díaz-Montero; Amir A Al-Khami; Sabry A El-Naggar; Osama Naga; Alberto J Montero; Ahmed Khafagy; David J Cole
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

10.  Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.

Authors:  Deepa Rajagopal; Carine Paturel; Yannis Morel; Satoshi Uematsu; Shizuo Akira; Sandra S Diebold
Journal:  Blood       Date:  2010-01-11       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.